Mariusz Shrestha
Overview
Explore the profile of Mariusz Shrestha including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
10
Citations
219
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Jiang Z, Ju Y, Ali A, Chung P, Wang D, Liu J, et al.
Cancers (Basel)
. 2023 Nov;
15(22).
PMID: 38001575
The metastasis of tumor cells into vital organs is a major cause of death from diverse types of malignancies [...].
2.
Jiang Z, Ju Y, Ali A, Chung P, Skowron P, Wang D, et al.
Nat Commun
. 2023 Jul;
14(1):4313.
PMID: 37463901
Metastatic breast-cancer is a major cause of death in women worldwide, yet the relationship between oncogenic drivers that promote metastatic versus primary cancer is still contentious. To elucidate this relationship...
3.
Shrestha M, Wang D, Ben-David Y, Zacksenhaus E
Oncogenesis
. 2023 May;
12(1):29.
PMID: 37230983
Immune-checkpoint (IC) modulators like the poliovirus receptor (PVR) and programmed death ligand 1 (PD-L1) attenuate innate and adaptive immune responses and are potential therapeutic targets for diverse malignancies, including triple-negative...
4.
Shrestha M, Blay S, Liang S, Swanson D, Lerner-Ellis J, Dickson B, et al.
J Mol Diagn
. 2023 Mar;
25(6):320-330.
PMID: 36958423
Next-generation sequencing is a superior method for detecting known and novel RNA fusions in formalin-fixed, paraffin-embedded tissue over fluorescence in situ hybridization and RT-PCR. However, confidence in fusion calling and...
5.
Faruq O, Zhao D, Shrestha M, Vecchione A, Zacksenhaus E, Chang H
Cancers (Basel)
. 2022 Mar;
14(6).
PMID: 35326742
Background: MDM2 is elevated in multiple myeloma (MM). Although traditionally, MDM2 negatively regulates p53, a growing body of research suggests that MDM2 plays several p53-independent roles in cancer pathogenesis as...
6.
Ren Z, Shrestha M, Sakamoto T, Melkman T, Meng L, Cairns R, et al.
Leukemia
. 2019 Nov;
34(4):1172-1176.
PMID: 31728055
No abstract available.
7.
Zacksenhaus E, Liu J, Granieri L, Vorobieva I, Wang D, Ghanbari-Azarnier R, et al.
Mol Cell Oncol
. 2018 Sep;
5(4):e1481814.
PMID: 30250928
The dual phosphatase CDC25 has recently been identified as a target for diverse triple-negative breast cancers including -deficient tumors. Moreover, CDC25 inhibitors effectively synergize with PI3K inhibitors to suppress tumor...
8.
Liu J, Granieri L, Shrestha M, Wang D, Vorobieva I, Rubie E, et al.
Cell Rep
. 2018 Apr;
23(1):112-126.
PMID: 29617654
CDK4/6 inhibitors are effective against cancer cells expressing the tumor suppressor RB1, but not RB1-deficient cells, posing the challenge of how to target RB1 loss. In triple-negative breast cancer (TNBC),...
9.
Zacksenhaus E, Shrestha M, Liu J, Vorobieva I, Chung P, Ju Y, et al.
Trends Cancer
. 2017 Nov;
3(11):768-779.
PMID: 29120753
A switch from catabolic to anabolic metabolism, a major hallmark of cancer, enables rapid cell duplication, and is driven by multiple oncogenic alterations, including PIK3CA mutation, MYC amplification, and TP53...
10.
Jones R, Robinson T, Liu J, Shrestha M, Voisin V, Ju Y, et al.
J Clin Invest
. 2016 Aug;
126(10):3739-3757.
PMID: 27571409
Triple-negative breast cancer (TNBC) includes basal-like and claudin-low subtypes for which no specific treatment is currently available. Although the retinoblastoma tumor-suppressor gene (RB1) is frequently lost together with TP53 in...